{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T03:16:07Z","timestamp":1768792567915,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1995,6,1]],"date-time":"1995-06-01T00:00:00Z","timestamp":801964800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur. J. Drug Metab. Pharmacokinet."],"published-print":{"date-parts":[[1995,6]]},"DOI":"10.1007\/bf03226364","type":"journal-article","created":{"date-parts":[[2012,2,22]],"date-time":"2012-02-22T23:51:26Z","timestamp":1329954686000},"page":"113-118","source":"Crossref","is-referenced-by-count":10,"title":["Biliary lipids, lithogenic index and biliary drug concentrations during etofibrate and bezafibrate treatment"],"prefix":"10.1007","volume":"20","author":[{"given":"R.","family":"Raedsch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Plachky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Simonis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF03226364_CR1","first-page":"113","volume":"2","author":"Recommendations of the European Atherosclerosis Society prepared by the International Task Force for Prevention of Coronary Heart Disease","year":"1992","unstructured":"Recommendations of the European Atherosclerosis Society prepared by the International Task Force for Prevention of Coronary Heart Disease (1992): Prevention of coronary heart disease: scientific background and new clinical guidelines. Nutr. Metab. Cardiovasc. Dis., 2, 113\u2013156.","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"BF03226364_CR2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00041433-199002000-00008","volume":"1","author":"S. Eisenberg","year":"1990","unstructured":"Eisenberg S. (1990): Role of fibric acids in the management of hyperlipidemia. Curr. Opin. Lipidol., 1, 34\u201338.","journal-title":"Curr. Opin. Lipidol."},{"key":"BF03226364_CR3","first-page":"107","volume-title":"Drug Treatment of Hyperlipidemia","author":"D.R. Illingworth","year":"1991","unstructured":"Illingworth D.R. (1991): Fibric acid derivatives. In: Rifkind B.M. (ed), Drug Treatment of Hyperlipidemia. New York, Marcel Dekker, 107\u2013131."},{"key":"BF03226364_CR4","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0021-9150(88)90019-6","volume":"69","author":"J.J. Series","year":"1988","unstructured":"Series J.J., Caslake M.J., et al. (1988): Influence of etofibrate on low density lipoprotein metabolism. Atherosclerosis, 69, 233\u2013239.","journal-title":"Atherosclerosis"},{"key":"BF03226364_CR5","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/00003495-198733060-00002","volume":"33","author":"J.P. Monk","year":"1987","unstructured":"Monk J.P., Todd P.A. (1987): Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia. Drugs, 33, 539\u2013576.","journal-title":"Drugs"},{"key":"BF03226364_CR6","first-page":"309","volume-title":"Pharmacological Control of Hyperlipidaemia","author":"R. Hendricks","year":"1986","unstructured":"Hendricks R., Jensen K.G. (1986): Comparison of the lipid-lowering action of bezafibrate retard and etofibrate retard in patients with type IIb hyperlipoproteinemia. In: Pharmacological Control of Hyperlipidaemia. JR Prous Science Publishers, SA, 309\u2013318."},{"key":"BF03226364_CR7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/BF03259858","volume":"2","author":"L.C. Knodel","year":"1987","unstructured":"Knodel L.C., Talbert R.L. (1987): Adverse effects of hypolipidaemic drugs. Med. Toxicol., 2, 10\u201332.","journal-title":"Med. Toxicol."},{"issue":"suppl 5B","key":"BF03226364_CR8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0002-9343(87)90869-2","volume":"83","author":"R.H. Palmer","year":"1987","unstructured":"Palmer R.H. (1987): Effects of fibric acid derivatives on biliary lipid composition. Am. J. Med., 83 (suppl 5B), 37\u201343.","journal-title":"Am. J. Med."},{"key":"BF03226364_CR9","first-page":"297","volume-title":"Pharmacological Control of Hyperlipidaemia","author":"W. Schatton","year":"1986","unstructured":"Schatton W., Schwaier A., Holderegger C., Quack G. (1986): Comparative effects of etofibrate and bezafibrate on liver structure and function, bile lithogenicity, and biliary elimination in rats. In: Pharmacological Control of Hyperlipidaemia. JR Prous Science Publishers, SA, 297\u2013307."},{"key":"BF03226364_CR10","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/1043-6618(89)90198-9","volume":"21","author":"E. Fabiani De","year":"1989","unstructured":"De Fabiani E., Crestani M., et al. (1989): The effect of etofibrate on cholesterol and bile acid metabolism in the hamster. Pharmacol. Res., 21, 567\u2013576.","journal-title":"Pharmacol. Res."},{"key":"BF03226364_CR11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0021-9150(80)90213-0","volume":"36","author":"G. Schlierf","year":"1980","unstructured":"Schlierf G., Chwat M., et al. (1980): Biliary and plasma lipids and lipid-lowering chemotherapy. Atherosclerosis, 36, 323\u2013329.","journal-title":"Atherosclerosis"},{"key":"BF03226364_CR12","volume-title":"Untersuchungen zur Lithogenit\u00e4t von Clofibratderivaten","author":"J. Kn\u00fcppel","year":"1984","unstructured":"Kn\u00fcppel J. (1984) Untersuchungen zur Lithogenit\u00e4t von Clofibratderivaten. PhD Thesis, Philipps-Universit\u00e4t Marburg, Germany."},{"key":"BF03226364_CR13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2165\/00003088-197803060-00001","volume":"3","author":"R. Gugler","year":"1978","unstructured":"Gugler R. (1978): Clinical pharmacokinetics of hypolipidaemic Drugs. Clin. Pharmacokinet., 3, 425\u2013439.","journal-title":"Clin. Pharmacokinet."},{"key":"BF03226364_CR14","first-page":"101","volume-title":"Lipoproteins and Coronary Heart Disease","author":"F.H. Schmidt","year":"1980","unstructured":"Schmidt F.H., Stegmeier K., et al. (1980): Pharmacokinetics and metabolism of bezafibrate in animals. In: Greten H., et al. (eds), Lipoproteins and Coronary Heart Disease. Baden-Baden, Witzstrock, 101\u2013104."},{"key":"BF03226364_CR15","unstructured":"Hummel K. (1991): Bestimmung von Bezafibrat und Clofibrins\u00e4ure. Merz Analytical Report."},{"key":"BF03226364_CR16","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/0016-5085(78)90068-9","volume":"75","author":"A. Stiehl","year":"1978","unstructured":"Stiehl A., Czygan P., Kommerell B., et al. (1978): Ursodeoxycholic acid versus chenodeoxycholic acid. Comparison of their effects on bile acids and lipid composition in patients with cholesterol gallstones. Gastroenterology, 75, 1016\u20131020.","journal-title":"Gastroenterology"},{"key":"BF03226364_CR17","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0016-5085(19)33056-2","volume":"65","author":"P.J. Thomas","year":"1973","unstructured":"Thomas P.J., Hofmann A.F. (1973): A simple calculation of the lithogenic index of bile: expressing biliary lipid composition on rectangular coordinanates. Gastroenterology, 65, 898\u2013900.","journal-title":"Gastroenterology"},{"key":"BF03226364_CR18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF02020933","volume":"10","author":"F. Hegardt","year":"1971","unstructured":"Hegardt F., Dam H. (1971): The solubility of cholesterol in aqueous solutions of bile salts and lecithin. Z. Ern\u00e4hrungswiss., 10, 223\u2013233.","journal-title":"Z. Ern\u00e4hrungswiss."},{"key":"BF03226364_CR19","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1172\/JCI107321","volume":"52","author":"R.T. Holzbach","year":"1973","unstructured":"Holzbach R.T., Marsh M., Oiszewski M., et al. (1973): Cholesterol solubility in bile. Evidence that supersaturated bile is frequent in healthy man. J. Clin. Invest., 52, 1467\u20131479.","journal-title":"J. Clin. Invest."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03226364.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03226364\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03226364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T00:16:11Z","timestamp":1561335371000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03226364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,6]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1995,6]]}},"alternative-id":["BF03226364"],"URL":"https:\/\/doi.org\/10.1007\/bf03226364","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,6]]}}}